Skip to main content
SpringerLink
Log in

Cell Cycle Regulators (p21, p53, pRb) in Oligodendrocytic Tumors: a Study by Novel Tumor Microarray Technique

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Using the novel tissue microarray technique, we studied immunohistochemical expression of cell cycle regulators p53, p21, pRb in 42 grade II oligodendrogliomas, 16 grade III anaplastic oligodendrogliomas, 10 primary and 4 recidive grade II oligoastrocytomas, 10 grade III oligoastrocytomas and 2 other grade II mixed gliomas. The p53 immunopositivity associated with malignant histology of the tumor (p = 0.01, Mann–Whitney test) and high pRb expression (p = 0.015). The p21 score associated strongly with histological grade (p 0.001). The immunopositive tumors had a significantly higher rate of proliferation (p = 0.021). The p21 immunopositivity correlated positively with p53 immunopositivity: among the 33 p21 immunopositive tumors 30 (91%) were p53 immunopositive and only 3 were p53 immunonegative (p = 0.017). Patients with p21 immunonegative primary tumors had significantly better prognosis: among them 42 of the 46 (91%) survived, whereas only 18 of the 30 patients (60%) with p21 immunopositive primary tumors survived until the follow-up date (p = 0.0017). Statistical significance was reached in multivariate analysis as well (p = 0.01, exp(B) = 5.5). The pRb immunopositive tumors had higher proliferation rate than immunonegative tumors (p = 0.002). In multivariate variance analysis, comparing the effects of different regulatory proteins on cell proliferation, only the amount of pRb expression reached statistical significance (p = 0.004). In conclusion, the expression of p21 in oligodendrocytic tumors seems to be upregulated by p53 expression which rises with cell proliferation and malignancy as in attempt to halt cell cycle but seems to be overrun by other factors. The amount of p21 expression has independent prognostic significance and could be used in diagnosis to help the difficult evaluation of the malignancy potential of oligodendrogliomas and oligoastrocytomas.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kraus JA, Koopmann J, Kaskel P, Maintz D, Brandner S, Schramm J, Louis DN, Wiestler OD, von Deimling A: Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol 54(1): 91–5, 1995

    Google Scholar 

  2. Maintz D, Fiedler K, Koopmann J, Rollbrocker B, Nechev S, Lenartz D, Stangl AP, Louis DN, Schramm J, Wiestler OD, von Deimling A: Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol 56: 1098–104, 1997

    Google Scholar 

  3. Perry JR, Louis DN, Cairncross JG: Current treatment of oligodendrogliomas. Arch Neurol 56(4): 434–6, 1999

    Google Scholar 

  4. Dirks PB, Rutka JT: Current concepts in neuro-oncology: the cell cycle - a review. Neurosurgery 40(5): 1000–15, 1997

    Google Scholar 

  5. Bartek J, Lukas J, Bartkova J: Perspective: defects in cell cycle control and cancer. J Pathol 187(1): 95–9, 1999

    Google Scholar 

  6. Ginsberg D, Mechta F, Yaniv M, Oren M: Wild-type p53 can down-modulate the activity of various promoters. Proc Natl Acad Sci USA 88: 9979–83, 1991

    Google Scholar 

  7. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304–11, 1991

    Google Scholar 

  8. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB: Wildtype p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89: 7491–5, 1992

    Google Scholar 

  9. Pavelic J, Hlavka V, Poljak M, Gale N, Pavelic K: p53 immunoreactivity in oligodendrogliomas. J Neuro-Oncol 22: 1–6, 1994

    Google Scholar 

  10. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817–25, 1993

    Google Scholar 

  11. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805–16, 1993

    Google Scholar 

  12. Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, Hannon GJ: Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377: 552–7, 1995

    Google Scholar 

  13. Waldman T, Kinzler KW, Vogelstein B: p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 55: 5187–90, 1995

    Google Scholar 

  14. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D: Induction ofWAF1/CIP1 by a p53-independent pathway. Cancer Res 54: 3391–5, 1994

    Google Scholar 

  15. Parker SB, Eichele G, Zhang P, Rawls A, Sands AT, Bradley A, Olson EN, Harper JW, Elledge SJ: p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells. Science 267: 1024–7, 1995

    Google Scholar 

  16. Arvanitis D, Malliri A, Antoniou D, Linardopoulos S, Field JK, Spandidos DA: Ras p21 expression in brain tumors: elevated expression in malignant astrocytomas and glioblastomas multiforme. In Vivo 5: 317–21, 1991

    Google Scholar 

  17. Jung JM, Bruner JM, Ruan S, Langford LA, Kyritsis AP, Kobayashi T, Levin VA, Zhang W: Increased levels of p21WAF1/Cip1 in human brain tumors. Oncogene 11: 2021–8, 1995

    Google Scholar 

  18. Korkolopoulou P, Kouzelis K, Christodoulou P, Papanikolaou A, Thomas-Tsagli E: Expression of retinoblastoma gene product and p21 (WAF1/Cip 1) protein in gliomas: correlations with proliferation markers, p53 expression and survival. Acta Neuropathol 95: 617–24, 1998

    Google Scholar 

  19. Koopmann J, Maintz D, Schild S, Schramm J, Louis DN, Wiestler OD, von Deimling A: Multiple polymorphisms, but no mutations, in the WAF1/CIP1 gene in human brain tumours. Br J Cancer 72: 1230–3, 1995

    Google Scholar 

  20. Friend SH, Bernards R, Rogelj S, Weinberg RA, Rapaport JM, Albert DM, Dryja TP: A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 328: 643–6, 1986

    Google Scholar 

  21. Weinberg R: The retinoblastoma protein and cell cycle control. Cell 81: 323–330, 1993

    Google Scholar 

  22. Toguchida J, Ishizaki K, Sasaki MS, Nakamura Y, Ikenaga M, Kato M, Sugimot M, Kotoura Y, Yamamuro T: Preferential mutation of paternally derived RB gene as the initial event in sporadic osteosarcoma. Nature 338: 156–8, 1989

    Google Scholar 

  23. Harbour JW, Lai SL, Whang-Peng J, Gazdar AF, Minna JD, Kaye FJ: Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science 241: 353–7, 1988

    Google Scholar 

  24. Lee EY, To H, Shew JY, Bookstein R, Scully P, Lee WH: Inactivation of the retinoblastoma susceptibility gene in human breast cancers. Science 241: 218–21, 1988

    Google Scholar 

  25. Henson JW, Schnitker BL, Correa KM, von Deimling A, Fassbender F, Xu HJ, Benedict WF, Yandell DW, Louis DN: The retinoblastoma gene is involved in malignant progression of astrocytomas. Ann Neurol 36: 714–21, 1994

    Google Scholar 

  26. Broholm H, Bols B, Heegaard S, Braendstrup O: Immunohistochemical investigation of p53 and EGFR expression of oligodendrogliomas. Clin Neuropathol 18: 176–80, 1999

    Google Scholar 

  27. Kros JM, Godschalk JJ, Krishnadath KK, Van Eden CG: Expression of p53 in oligodendrogliomas. J Pathol 171(4): 285–90, 1993

    Google Scholar 

  28. Ohgaki H, Eibl RH, Wiestler OD, Yasargil MG, Newcomb EW, Kleihues P: p53 mutations in nonastrocytic human brain tumors. Cancer Res 51(22): 6202–5, 1991

    Google Scholar 

  29. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4: 844–7, 1998

    Google Scholar 

  30. Theillet C: Full speed ahead for tumor screening. Nat Med 4: 767–8, 1998

    Google Scholar 

  31. Moch H, Schraml P, Bubendorf L, Mirlacher M, Kononen J, Gasser T, Mihatsch MJ, Kallioniemi OP, Sauter G: Highthroughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am J Pathol 154: 981–6, 1999

    Google Scholar 

  32. Bubendorf L, Kolmer M, Kononen J, Koivisto P, Mousses S, Chen Y, Mahlamaki E, Schraml P, Moch H, Willi N, Elkahloun AG, Pretlow TG, Gasser TC, Mihatsch MJ, Sauter G, Kallioniemi OP: Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. J Natl Cancer Inst 91: 1758–64, 1999

    Google Scholar 

  33. Kleihues P, Burger PC, Scheithauer BW: Histological Typing of Tumours of the Central Nervous System. WHO. Berlin: Springer-Verlag, 1993

    Google Scholar 

  34. Sallinen P, Haapasalo HK, Visakorpi T, Helén P, Rantala IS, Isola JJ: Prognostication of astrocytoma patient survival by Ki-67 (MIB-1), PCNA, and S-phase fraction using archival paraffin-embedded samples. J Pathol 174: 275–82, 1994

    Google Scholar 

  35. Reifenberger J, Ring GU, Gies U, Cobbers L, Oberstrass J, An HX, Niederacher D, Wechsler W, Reifenberger G: Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression. J Neuropathol Exp Neurol 55(7): 822–31, 1996

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Tampere University Hospital, Tampere, Finland

    Helena E. Miettinen, Niina Paunu, Immo Rantala, Heikki Helin & Hannu Haapasalo

  2. Department of Pathology, Turku University and Turku University Hospital, Turku, Finland

    Hannu Kalimo

  3. Department of Pathology, Kuopio University and Kuopio University Hospital, Kuopio, Finland

    Leo Paljärvi

Authors
  1. Helena E. Miettinen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Niina Paunu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Immo Rantala
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hannu Kalimo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Leo Paljärvi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Heikki Helin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hannu Haapasalo
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Miettinen, H.E., Paunu, N., Rantala, I. et al. Cell Cycle Regulators (p21, p53, pRb) in Oligodendrocytic Tumors: a Study by Novel Tumor Microarray Technique. J Neurooncol 55, 29–37 (2001). https://doi.org/10.1023/A:1012961918848

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1012961918848

Search

Navigation